CytoDyn terminates CEO Nader Pourhassan; CFO Migliarese named interim president

CytoDyn Inc.

Board terminated CEO Nader Z. Pourhassan on Jan 24, 2022; he also resigned from the board.
Antonio Migliarese, current CFO, elected interim president; a committee will search for a permanent CEO.
Tanya Durkee Urbach elected Chairman of the Board; Scott Kelly remains CMO and director.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nader Z. Pourhassan

President and Chief Executive Officer

CYDY · CytoDyn Inc.

Effective: 2022-01-24
Filed: January 27, 2022, 6:59 PM ET

On January 24, 2022, the Board of Directors (the “Board”) of CytoDyn Inc. (the “Company”) terminated the employment of the Company’s President and Chief Executive Officer, Nader Z. Pourhassan, Ph.D., and removed him as an officer of the Company.

Appointed (interim)

Antonio Migliarese

interim President

CYDY · CytoDyn Inc.

Effective: 2022-01-24
Filed: January 27, 2022, 6:59 PM ET

Also on January 24, 2022, the Board elected Antonio Migliarese interim President of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nader Z. Pourhassan was terminated as President and Chief Executive Officer at CytoDyn Inc..

Action: terminated
Role: President and Chief Executive Officer

Exact text from the filing

On January 24, 2022, the Board of Directors (the “Board”) of CytoDyn Inc. (the “Company”) terminated the employment of the Company’s President and Chief Executive Officer, Nader Z. Pourhassan, Ph.D., and removed him as an officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Antonio Migliarese was elected as interim President at CytoDyn Inc..

Action: elected
Role: interim President

Exact text from the filing

Also on January 24, 2022, the Board elected Antonio Migliarese interim President of the Company.

View on SEC.gov

CytoDyn Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-019977

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.